$ALXO
ALX ONCOLOGY HOLDINGS INC

2024 Q1 Form 10-K Financial Statement

#000095017024027955 Filed on March 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.045M $6.239M $28.48M
YoY Change -18.75% -11.15% -1.9%
% of Gross Profit
Research & Development $31.72M $41.78M $141.8M
YoY Change 28.08% 65.83% 44.1%
% of Gross Profit
Depreciation & Amortization $214.0K $207.0K $836.0K
YoY Change 0.47% 97.14% 144.44%
% of Gross Profit
Operating Expenses $37.76M $48.02M $170.3M
YoY Change 17.26% 49.05% 33.62%
Operating Profit -$37.76M -$170.3M
YoY Change 17.26% 33.62%
Interest Expense $427.0K $2.580M $1.565M
YoY Change 10.34% 42.78% -63.42%
% of Operating Profit
Other Income/Expense, Net -$14.00K -$29.00K $389.0K
YoY Change -114.74% -87.55% -249.62%
Pretax Income -$35.58M -$45.47M -$160.8M
YoY Change 17.88% 48.38% 30.29%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$35.58M -$45.47M -$160.8M
YoY Change 17.88% 48.07% 30.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.71 -$3.74
Diluted Earnings Per Share -$0.71 -$0.93 -$3.74
COMMON SHARES
Basic Shares Outstanding 50.15M 49.82M 42.99M
Diluted Shares Outstanding 50.12M 42.99M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.4M $182.7M $182.7M
YoY Change -30.93% -31.36% -31.36%
Cash & Equivalents $14.04M $22.41M $22.41M
Short-Term Investments $143.4M $160.3M $160.3M
Other Short-Term Assets $9.327M $4.923M $4.923M
YoY Change 103.11% 3.38% 3.38%
Inventory
Prepaid Expenses $830.0K
Receivables
Other Receivables
Total Short-Term Assets $167.9M $188.7M $188.7M
YoY Change -27.81% -30.38% -30.38%
LONG-TERM ASSETS
Property, Plant & Equipment $3.441M $3.589M $10.84M
YoY Change -12.49% -7.71% 10.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $27.05M $35.41M $35.41M
YoY Change -4.15% 112.05% 112.05%
Other Assets $14.30M $14.89M $7.642M
YoY Change 6.29% -0.25% -15.39%
Total Long-Term Assets $44.79M $53.89M $53.89M
YoY Change -1.79% 51.73% 51.73%
TOTAL ASSETS
Total Short-Term Assets $167.9M $188.7M $188.7M
Total Long-Term Assets $44.79M $53.89M $53.89M
Total Assets $212.7M $242.6M $242.6M
YoY Change -23.55% -20.86% -20.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.227M $8.591M $8.591M
YoY Change -36.63% 6.42% 6.42%
Accrued Expenses $24.66M $26.05M $26.05M
YoY Change 112.05% 31.63% 31.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $728.0K
YoY Change 154.55%
Total Short-Term Liabilities $32.23M $36.00M $36.00M
YoY Change 47.22% 27.1% 27.1%
LONG-TERM LIABILITIES
Long-Term Debt $9.703M $9.639M $11.21M
YoY Change 2.68% 2.66% 19.41%
Other Long-Term Liabilities $6.524M $7.201M $5.629M
YoY Change 1.79% 35.59% 5.99%
Total Long-Term Liabilities $16.23M $16.84M $16.84M
YoY Change 2.32% 14.56% 14.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.23M $36.00M $36.00M
Total Long-Term Liabilities $16.23M $16.84M $16.84M
Total Liabilities $48.46M $52.84M $52.84M
YoY Change 28.36% 22.81% 22.81%
SHAREHOLDERS EQUITY
Retained Earnings -$521.9M -$486.3M
YoY Change 46.73% 49.41%
Common Stock $686.0M $675.7M
YoY Change 15.08% 14.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $164.2M $189.7M $189.7M
YoY Change
Total Liabilities & Shareholders Equity $212.7M $242.6M $242.6M
YoY Change -23.55% -20.86% -20.86%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$35.58M -$45.47M -$160.8M
YoY Change 17.88% 48.07% 30.23%
Depreciation, Depletion And Amortization $214.0K $207.0K $836.0K
YoY Change 0.47% 97.14% 144.44%
Cash From Operating Activities -$37.92M -$39.68M -$130.4M
YoY Change 36.34% 91.98% 46.11%
INVESTING ACTIVITIES
Capital Expenditures $148.0K $148.0K $1.274M
YoY Change -78.55% -61.95% -10.72%
Acquisitions
YoY Change
Other Investing Activities $26.62M -$16.52M $45.93M
YoY Change -38.07% -245.78% -119.63%
Cash From Investing Activities $26.47M -$16.67M $44.66M
YoY Change -37.41% -252.31% -118.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.086M 59.17M 59.29M
YoY Change -2984.11% 523.19% 501.33%
NET CHANGE
Cash From Operating Activities -37.92M -39.68M -130.4M
Cash From Investing Activities 26.47M -16.67M 44.66M
Cash From Financing Activities 3.086M 59.17M 59.29M
Net Change In Cash -8.365M 2.822M -26.42M
YoY Change -158.2% -1316.38% -91.61%
FREE CASH FLOW
Cash From Operating Activities -$37.92M -$39.68M -$130.4M
Capital Expenditures $148.0K $148.0K $1.274M
Free Cash Flow -$38.07M -$39.83M -$131.6M
YoY Change 33.56% 89.13% 45.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001810182
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39386
CY2023 dei Entity Registrant Name
EntityRegistrantName
ALX ONCOLOGY HOLDINGS INC
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0642577
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
323 Allerton Avenue
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
466-7125
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
ALXO
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
161400000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50152082
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22406000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48822000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
160330000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
217385000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5923000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4762000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
188659000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
270969000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3589000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3889000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
35411000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
16699000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14894000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14932000
CY2023Q4 us-gaap Assets
Assets
242553000
CY2022Q4 us-gaap Assets
Assets
306489000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8591000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8073000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
543000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1650000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
26867000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18602000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36001000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28325000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9639000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9389000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7201000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5311000
CY2023Q4 us-gaap Liabilities
Liabilities
52841000
CY2022Q4 us-gaap Liabilities
Liabilities
43025000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49951989
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49951989
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40861386
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40861386
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
675678000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
589735000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
256000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-845000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-486272000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-325467000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
189712000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
263464000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
242553000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306489000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
141795000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98400000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60170000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28483000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29036000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23385000
CY2023 us-gaap Operating Expenses
OperatingExpenses
170278000
CY2022 us-gaap Operating Expenses
OperatingExpenses
127436000
CY2021 us-gaap Operating Expenses
OperatingExpenses
83555000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-170278000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-127436000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-83555000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
10649000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
4278000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
91000
CY2023 us-gaap Interest Expense
InterestExpense
1565000
CY2022 us-gaap Interest Expense
InterestExpense
238000
CY2021 us-gaap Interest Expense
InterestExpense
13000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
389000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-160805000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123418000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83484000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
64000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-21000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-160805000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-123482000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83463000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.74
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.74
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.03
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.03
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.07
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.07
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42987767
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42987767
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40699612
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40699612
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40308050
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40308050
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-160805000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-123482000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83463000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1101000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-845000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-159704000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124327000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83463000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
429845000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2551000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
202000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13914000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83463000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
567000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
336000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23839000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-845000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-123482000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
263464000
CY2023 alxo Payments For Underwriter Discounts
PaymentsForUnderwriterDiscounts
3800000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
600000
CY2023 alxo Issuance Of Common Stock And Pre Funded Warrants In Connection With Equity Offerings Net Of Underwriter Discounts And Issuance Costs
IssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithEquityOfferingsNetOfUnderwriterDiscountsAndIssuanceCosts
58887000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
269000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
523000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26273000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1101000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-160805000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
189712000
CY2023 us-gaap Profit Loss
ProfitLoss
-160805000
CY2022 us-gaap Profit Loss
ProfitLoss
-123482000
CY2021 us-gaap Profit Loss
ProfitLoss
-83463000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
836000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
342000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51000
CY2023 alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
1272000
CY2022 alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
1124000
CY2021 alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
685000
CY2021 alxo Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
4739000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
26273000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
23839000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
13914000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6487000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
940000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
250000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
44000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1291000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1476000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1662000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1366000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-750000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
9682000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
458000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4506000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3290000
CY2023 alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
-1107000
CY2022 alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
20000
CY2021 alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
1419000
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
11224000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
7027000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3306000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2353000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-977000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-698000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-130364000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89223000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68101000
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
246629000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
376789000
CY2023 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
292560000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
142800000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1274000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1427000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
666000
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4257000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
44657000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-235416000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4923000
CY2023 alxo Payments For Underwriter Discounts
PaymentsForUnderwriterDiscounts
3800000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
600000
CY2023 alxo Proceeds From Equity Offerings Net Of Underwriter Discounts And Issuance Costs
ProceedsFromEquityOfferingsNetOfUnderwriterDiscountsAndIssuanceCosts
58887000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
269000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
567000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2551000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
523000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
336000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
202000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
388000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
388000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
281000
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
655000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59291000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9860000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2472000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26416000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-314779000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-70552000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48888000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363667000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
434219000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22472000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48888000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363667000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1177000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
103000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
274000
CY2023 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
1407000
CY2022 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
2145000
CY2021 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
237000
CY2021 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
482000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4613000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1780000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
2600000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
776000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22406000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48822000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363667000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22472000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48888000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363667000
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain reclassifications have also been made within the consolidated statements of operations for the years ended December 31, 2022 and 2021 to conform to the current year presentation. For the year ended December 31, 2022, the Company reclassified approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million out of other expense, net into a separate interest expense financial statement line item and renamed other expense, net to other income (expense), net. For the year ended December 31, 2021, the Company reclassified less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million out of other expense, net into a separate interest income financial statement line item and renamed other expense, net to other income (expense), net. Total loss before income taxes as of December 31, 2022 and 2021 did not change as a result of these reclassifications.</span></p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including, but not limited to, those related to the estimated useful lives of long-lived assets, clinical and contract manufacturing accruals, fair value of assets and liabilities, fair value of investments, valuation of the Company’s common stock in periods prior to its initial public offering and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
8873000
CY2022Q4 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
5485000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6067000
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3708000
CY2023Q4 alxo Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
179000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215822000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274258000
CY2023Q4 us-gaap Cash
Cash
2300000
CY2022Q4 us-gaap Cash
Cash
8600000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
180411000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
257559000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
35411000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
16699000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215822000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274258000
CY2023 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2022 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1000000
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1000000
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
5900000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2023 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2022 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2022Q4 alxo Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
2110000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4826000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4292000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1237000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
403000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3589000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3889000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4847000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5626000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2405000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
298000
CY2023Q4 alxo Other Assets Noncurrent Other
OtherAssetsNoncurrentOther
200000
CY2022Q4 alxo Other Assets Noncurrent Other
OtherAssetsNoncurrentOther
288000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14894000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14932000
CY2023Q4 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
9543000
CY2022Q4 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
5249000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
88000
CY2023 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
493000
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
447000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2205000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2050000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
26867000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18602000
CY2023 us-gaap Lessee Finance Lease Option To Extend
LesseeFinanceLeaseOptionToExtend
no
CY2023 us-gaap Lessee Finance Lease Description
LesseeFinanceLeaseDescription
In May 2023, the Company entered into an addendum to extend the existing lease through May 2026 and lease additional number of certain equipment. In October 2023, the Company entered into an additional addendum to lease an additional number of certain equipment through May 2026.
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4800000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2400000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5600000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
300000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
1267000
CY2023Q4 us-gaap Finance Lease Liability Payments Due In Next Rolling Twelve Months
FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
1056000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
1305000
CY2023Q4 us-gaap Finance Lease Liability Payments Due In Rolling Year Two
FinanceLeaseLiabilityPaymentsDueInRollingYearTwo
1056000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
1187000
CY2023Q4 us-gaap Finance Lease Liability Payments Due In Rolling Year Three
FinanceLeaseLiabilityPaymentsDueInRollingYearThree
440000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
912000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
939000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
1130000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6740000
CY2023Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2552000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1482000
CY2023Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
252000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5258000
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
2300000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
847000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
728000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4411000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1572000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5258000
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
2300000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.087
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.085
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1263000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1159000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
360000
CY2023 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
461000
CY2022 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
262000
CY2021 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
84000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
369000
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
44000
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
9000
CY2021 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
13000
CY2023 us-gaap Lease Cost
LeaseCost
2278000
CY2022 us-gaap Lease Cost
LeaseCost
1965000
CY2021 us-gaap Lease Cost
LeaseCost
826000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1241000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
933000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
243000
CY2023 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
20000
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
8000
CY2021 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
11000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
388000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
388000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
281000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4613000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1780000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
2600000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
776000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
435000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5217000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4948000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10600000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q4 alxo Term Loan Non Current
TermLoanNonCurrent
10600000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
781000
CY2023Q4 alxo Term Loan Unamortized Final Payment
TermLoanUnamortizedFinalPayment
180000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9639000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49951989
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40861386
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12305115
CY2023 alxo Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6196848
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.56
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M10D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19872000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3139800
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.03
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
54359
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.95
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
297618
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8984671
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.43
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M10D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
59900000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4704798
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.47
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M7D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
30924000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1700000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
48100000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13914000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
38900000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.047
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.044
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.008
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.836
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.886
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.819
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.847
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.797
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.869
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.44
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.88
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
42.29
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26273000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23839000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-159766000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-111360000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30565000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1039000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-12058000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-52919000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-160805000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123418000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83484000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
64000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-21000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
64000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-21000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
64000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-21000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-33769000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-25918000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-17532000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1481000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2659000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-105000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3645000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2368000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-4031000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
7185000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1779000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2131000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
64486000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9067000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
11476000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
189000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
36000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
172000
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-23000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
18949000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
11032000
CY2021 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
1098000
CY2023 alxo Income Tax Reconciliation Rate Benefit Of Reorganization
IncomeTaxReconciliationRateBenefitOfReorganization
-25862000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
64000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-21000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26517000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16319000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
17131000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
8435000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8076000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
14000
CY2023Q4 alxo Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
1014000
CY2022Q4 alxo Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
1860000
CY2023Q4 alxo Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
5157000
CY2022Q4 alxo Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
3860000
CY2023Q4 alxo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
1587000
CY2022Q4 alxo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
1323000
CY2023Q4 alxo Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
38425000
CY2022Q4 alxo Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
1702000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
97907000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
33513000
CY2023Q4 alxo Deferred Tax Liabilities Property Plant And Equipment1
DeferredTaxLiabilitiesPropertyPlantAndEquipment1
96000
CY2022Q4 alxo Deferred Tax Liabilities Property Plant And Equipment1
DeferredTaxLiabilitiesPropertyPlantAndEquipment1
215000
CY2023Q4 alxo Deferred Tax Liabilities Lease Right Of Use Assets
DeferredTaxLiabilitiesLeaseRightOfUseAssets
1523000
CY2022Q4 alxo Deferred Tax Liabilities Lease Right Of Use Assets
DeferredTaxLiabilitiesLeaseRightOfUseAssets
1244000
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
252000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1619000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1711000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96288000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31802000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
64500000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9100000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1700000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1200000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1661000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1217000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
842000
CY2023 alxo Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
81000
CY2022 alxo Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
13000
CY2021 alxo Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-69000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1409000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
443000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
494000
CY2023 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
31000
CY2022 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
12000
CY2021 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
50000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3120000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1661000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1217000
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-160805000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-123482000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83463000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42987767
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42987767
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40699612
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40699612
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40308050
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40308050
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.74
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.74
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.03
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.03
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.07
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.07
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9934340
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7017174
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5143714
CY2023Q4 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0
CY2022Q4 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0
CY2021Q4 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0
CY2023Q4 us-gaap Purchase Obligation
PurchaseObligation
6736000
CY2023Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
6535000
CY2023Q4 us-gaap Purchase Obligation Due In Second And Third Year
PurchaseObligationDueInSecondAndThirdYear
201000
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
6736000
CY2023Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
6535000
CY2023Q4 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
201000
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-027955-index-headers.html Edgar Link pending
0000950170-24-027955-index.html Edgar Link pending
0000950170-24-027955.txt Edgar Link pending
0000950170-24-027955-xbrl.zip Edgar Link pending
alxo-20231231.htm Edgar Link pending
alxo-20231231.xsd Edgar Link pending
alxo-ex21_1.htm Edgar Link pending
alxo-ex23_1.htm Edgar Link pending
alxo-ex31_1.htm Edgar Link pending
alxo-ex31_2.htm Edgar Link pending
alxo-ex32_1.htm Edgar Link pending
alxo-ex32_2.htm Edgar Link pending
alxo-ex4_3.htm Edgar Link pending
alxo-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img50887369_0.jpg Edgar Link pending
img50887369_1.jpg Edgar Link pending
img50887369_10.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
alxo-20231231_htm.xml Edgar Link completed
img50887369_11.jpg Edgar Link pending
img50887369_12.jpg Edgar Link pending
img50887369_13.jpg Edgar Link pending
img50887369_2.jpg Edgar Link pending
img50887369_3.jpg Edgar Link pending
img50887369_4.jpg Edgar Link pending
img50887369_5.jpg Edgar Link pending
img50887369_6.jpg Edgar Link pending
img50887369_7.jpg Edgar Link pending
img50887369_8.jpg Edgar Link pending
img50887369_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending